|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
|
US6134717A
(en)
|
1998-11-20 |
2000-10-24 |
Morning Pride Manufacturing, L.L.C. |
Protective garment with leg portions and with cuffs to prevent liquids from entering boots
|
|
ES2340499T3
(es)
|
2001-06-05 |
2010-06-04 |
Curevac Gmbh |
Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
|
|
EP2447370B1
(en)
|
2001-09-28 |
2018-07-18 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
MicroRNA molecules
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
US7245963B2
(en)
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
US10188083B2
(en)
|
2016-08-21 |
2019-01-29 |
Daniel Michael Leo |
Insect production systems and methods
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
|
EP1778283A2
(en)
|
2004-06-30 |
2007-05-02 |
ID Biomedical Corporation of Quebec |
Vaccine compositions for treating coronavirus infection
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
WO2007086881A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US8304529B2
(en)
|
2006-07-28 |
2012-11-06 |
Life Technologies Corporation |
Dinucleotide MRNA cap analogs
|
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
CA2689042A1
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
|
CN104072561B
(zh)
|
2007-06-19 |
2017-12-22 |
路易斯安那州州立大学及农业机械学院管理委员会 |
信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
DK2176408T5
(en)
|
2008-01-31 |
2015-12-14 |
Curevac Gmbh |
Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
|
|
EP2304452A4
(en)
|
2008-04-14 |
2014-12-03 |
Corp Nuvolt Inc |
METHOD AND SYSTEM FOR DETECTING ELECTRICAL ANOMALIES
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
PL215513B1
(pl)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
|
|
WO2010021865A1
(en)
|
2008-08-18 |
2010-02-25 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
EP3269395A1
(en)
|
2008-11-07 |
2018-01-17 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
CN111808084A
(zh)
|
2008-11-10 |
2020-10-23 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
EP2485770A4
(en)
|
2009-10-08 |
2013-04-10 |
Merck Sharp & Dohme |
Novel cationic lipids with short lipid chains for oligonucleotide delivery
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
US8808982B2
(en)
|
2009-12-07 |
2014-08-19 |
Cellscript, Llc |
Compositions and methods for reprogramming eukaryotic cells
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
CA3009891C
(en)
|
2009-12-23 |
2020-09-15 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
EP2525781A1
(en)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Novel cationic lipids for oligonucleotide delivery
|
|
WO2011143230A1
(en)
|
2010-05-10 |
2011-11-17 |
Alnylam Pharmaceuticals |
Methods and compositions for delivery of active agents
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
KR20190039347A
(ko)
|
2010-06-03 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
활성제의 전달을 위한 생분해성 지질
|
|
DK2575767T3
(en)
|
2010-06-04 |
2017-03-13 |
Sirna Therapeutics Inc |
HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
KR101761388B1
(ko)
|
2010-07-30 |
2017-07-25 |
큐어백 아게 |
트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
SI4043040T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
MX2013002332A
(es)
|
2010-08-31 |
2013-03-18 |
Novartis Ag |
Lipidos apropiados para suministro liposomal del arn que codifica la proteina.
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
CA2809858C
(en)
|
2010-09-20 |
2019-11-12 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
ES2795110T3
(es)
|
2011-06-08 |
2020-11-20 |
Translate Bio Inc |
Lípidos escindibles
|
|
RU2013154295A
(ru)
|
2011-06-08 |
2015-07-20 |
Шир Хьюман Дженетик Терапис, Инк. |
КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
|
|
EP4115875A1
(en)
|
2011-07-06 |
2023-01-11 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
MX366055B
(es)
|
2011-08-31 |
2019-06-26 |
Novartis Ag |
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
WO2013035563A1
(ja)
|
2011-09-08 |
2013-03-14 |
株式会社トクヤマ |
界面活性剤被覆半水石膏およびその製造方法
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
WO2013059475A1
(en)
|
2011-10-18 |
2013-04-25 |
Life Technologies Corporation |
Alkynyl-derivatized cap analogs, preparation and uses thereof
|
|
PE20181541A1
(es)
|
2011-10-27 |
2018-09-26 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
JP6182457B2
(ja)
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
MX362981B
(es)
|
2012-03-27 |
2019-02-28 |
Curevac Ag |
Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
|
|
WO2013143700A2
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
|
SG11201405542UA
(en)
|
2012-03-27 |
2014-10-30 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
WO2013174409A1
(en)
|
2012-05-25 |
2013-11-28 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
US9974845B2
(en)
|
2013-02-22 |
2018-05-22 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
|
ES2708562T3
(es)
|
2013-03-14 |
2019-04-10 |
Translate Bio Inc |
Evaluación cuantitativa de la eficacidad de tapa de ARN mensajero
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
BR112015022505A2
(pt)
|
2013-03-14 |
2017-10-24 |
Shire Human Genetic Therapies |
avaliação quantitativa para eficiência do cap de rna mensageiro
|
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
|
RU2016109938A
(ru)
|
2013-08-21 |
2017-09-26 |
Куревак Аг |
Композиция и вакцина для лечения рака предстательной железы
|
|
MY174677A
(en)
|
2013-08-21 |
2020-05-06 |
Curevac Ag |
Composition and vaccine for treating lung cancer
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
KR102354389B1
(ko)
|
2013-08-21 |
2022-01-20 |
큐어백 아게 |
Rna―암호화된 단백질의 발현을 증가시키는 방법
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
ES3032935T3
(en)
|
2013-10-22 |
2025-07-29 |
Translate Bio Inc |
Lipid formulations for delivery of messenger rna
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
AU2014348212C1
(en)
|
2013-11-18 |
2018-11-29 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
CN111304231A
(zh)
|
2013-12-30 |
2020-06-19 |
库瑞瓦格股份公司 |
人工核酸分子
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
US10369216B2
(en)
|
2014-04-01 |
2019-08-06 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
PL4023249T3
(pl)
|
2014-04-23 |
2025-03-10 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
US9850269B2
(en)
|
2014-04-25 |
2017-12-26 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
EP3155129B1
(en)
|
2014-06-10 |
2019-01-16 |
CureVac AG |
Method for enhancing rna production
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
US20180085391A1
(en)
|
2014-08-08 |
2018-03-29 |
Modernatx, Inc. |
Compositions and methods for the treatment of ophthalmic diseases and conditions
|
|
ES3015369T3
(en)
|
2014-10-09 |
2025-05-05 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
|
PT4023755T
(pt)
|
2014-12-12 |
2023-07-05 |
CureVac SE |
Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
|
|
EP3233113A1
(en)
|
2014-12-16 |
2017-10-25 |
CureVac AG |
Ebolavirus and marburgvirus vaccines
|
|
US20160188710A1
(en)
|
2014-12-29 |
2016-06-30 |
Wipro Limited |
METHOD AND SYSTEM FOR MIGRATING DATA TO NOT ONLY STRUCTURED QUERY LANGUAGE (NoSOL) DATABASE
|
|
EP3240558A1
(en)
|
2014-12-30 |
2017-11-08 |
CureVac AG |
Artificial nucleic acid molecules
|
|
EP3247363A4
(en)
|
2015-01-21 |
2018-10-03 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP3247398A4
(en)
|
2015-01-23 |
2018-09-26 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
|
CN108064176A
(zh)
|
2015-04-22 |
2018-05-22 |
库瑞瓦格股份公司 |
用于治疗肿瘤疾病的含有rna的组合物
|
|
AU2016253972B2
(en)
|
2015-04-27 |
2020-01-02 |
Acuitas Therapeutics Inc. |
Nucleoside-modified RNA for inducing an adaptive immune response
|
|
ES2897823T3
(es)
|
2015-04-30 |
2022-03-02 |
Curevac Ag |
Poli(N)polimerasa inmovilizada
|
|
SG11201708681SA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
WO2016184822A1
(en)
|
2015-05-15 |
2016-11-24 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mrna construct
|
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
EP4660315A3
(en)
|
2015-05-29 |
2026-03-18 |
CureVac Manufacturing GmbH |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
|
EP3303575B1
(en)
|
2015-05-29 |
2022-03-16 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
EP3317424B1
(en)
|
2015-07-01 |
2023-09-06 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
US20200085852A1
(en)
|
2015-08-05 |
2020-03-19 |
Curevac Ag |
Epidermal mrna vaccine
|
|
WO2017025120A1
(en)
|
2015-08-07 |
2017-02-16 |
Curevac Ag |
Process for the in vivo production of rna in a host cell
|
|
DE22195354T1
(de)
|
2015-08-10 |
2023-05-25 |
CureVac Manufacturing GmbH |
Verfahren zur erhöhung der replikation eines zirkulären dna-moleküls
|
|
WO2017036580A1
(en)
|
2015-08-28 |
2017-03-09 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
US10676511B2
(en)
|
2015-09-17 |
2020-06-09 |
Ramot At Tel-Aviv University Ltd. |
Coronaviruses epitope-based vaccines
|
|
CN120842296A
(zh)
|
2015-09-21 |
2025-10-28 |
垂林克生物技术有限公司 |
用于合成5’-加帽rna的组合物和方法
|
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017066793A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
SI3362461T1
(sl)
|
2015-10-16 |
2022-05-31 |
Modernatx, Inc. |
Analogi kape MRNA z modificirano fosfatno povezavo
|
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
|
JP7384512B2
(ja)
|
2015-10-22 |
2023-11-21 |
モデルナティエックス インコーポレイテッド |
広域インフルエンザウイルスワクチン
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
WO2017108087A1
(en)
|
2015-12-21 |
2017-06-29 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
|
EP3701963A1
(en)
|
2015-12-22 |
2020-09-02 |
CureVac AG |
Method for producing rna molecule compositions
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
US9834510B2
(en)
|
2015-12-30 |
2017-12-05 |
Arcturus Therapeutics, Inc. |
Aromatic ionizable cationic lipid
|
|
US12612654B2
(en)
|
2016-02-12 |
2026-04-28 |
CureVac SE |
Method for analyzing RNA
|
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
|
SG10201913630YA
(en)
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
US20190177714A1
(en)
|
2016-03-24 |
2019-06-13 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
|
EP3445392A1
(en)
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
EP4631970A3
(en)
|
2016-05-04 |
2026-01-07 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
US12508308B2
(en)
|
2016-05-04 |
2025-12-30 |
CureVac SE |
Influenza mRNA vaccines
|
|
WO2017203008A1
(en)
|
2016-05-25 |
2017-11-30 |
Curevac Ag |
Novel biomarkers
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
US20190336611A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
CN109475640B
(zh)
|
2016-06-09 |
2023-03-10 |
库瑞瓦格欧洲公司 |
核酸被运载物的混合载运体
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
CA3036831A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
FR3056365A1
(fr)
|
2016-09-19 |
2018-03-23 |
Stmicroelectronics Sa |
Procede de gestion du fonctionnement d'un circuit de bascule synchrone de retention de faible complexite, et circuit correspondant
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
US10960070B2
(en)
*
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
CA3040337A1
(en)
|
2016-10-26 |
2018-05-03 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
WO2018115527A2
(en)
*
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
SG11201906297QA
(en)
|
2017-03-24 |
2019-10-30 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
US10724437B2
(en)
|
2017-06-28 |
2020-07-28 |
General Electric Company |
Systems and methods for particle separator in a gas turbine engine
|
|
SG11201911430PA
(en)
|
2017-07-04 |
2020-01-30 |
Curevac Ag |
Novel nucleic acid molecules
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
CN111511924A
(zh)
|
2017-11-08 |
2020-08-07 |
库瑞瓦格股份公司 |
Rna序列调整
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
AU2019254591B2
(en)
|
2018-04-17 |
2025-12-11 |
CureVac SE |
Novel RSV RNA molecules and compositions for vaccination
|
|
US11964051B2
(en)
|
2018-05-16 |
2024-04-23 |
Translate Bio, Inc. |
Ribose cationic lipids
|
|
JP7488193B2
(ja)
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
US12240824B2
(en)
|
2018-05-30 |
2025-03-04 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
WO2019232208A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
CA3101484A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
WO2020002598A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
|
US10745919B1
(en)
|
2019-07-26 |
2020-08-18 |
Big Time Investment, Llc |
Method and apparatus for installing a staircase assembly into a building
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
CN110647053A
(zh)
|
2019-09-19 |
2020-01-03 |
北京智行者科技有限公司 |
一种自动驾驶仿真方法及系统
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
US20210222178A1
(en)
|
2020-01-11 |
2021-07-22 |
Sivec Biotechnologies Llc |
MICROBIAL SYSTEM FOR PRODUCTION AND DELIVERY OF EUKARYOTE-TRANSLATABLE mRNA TO EUKARYA
|
|
WO2021147025A1
(en)
|
2020-01-22 |
2021-07-29 |
The University Of Hong Kong-Shenzhen Hospital |
Anti 2019-ncov vaccine
|
|
MX2022009001A
(es)
|
2020-01-24 |
2022-10-27 |
Aim Immunotech Inc |
Arn bicatenario terapéutico y métodos para producirlo.
|
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
|
BR112022014737A2
(pt)
|
2020-01-27 |
2022-12-20 |
Valent Usa Llc |
Composição aquosa, e, método para controlar uma praga
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
PH12022551788A1
(en)
|
2020-01-28 |
2024-02-26 |
Codagenix Inc |
DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF
|
|
JP2023511633A
(ja)
|
2020-01-28 |
2023-03-20 |
モデルナティエックス インコーポレイテッド |
コロナウイルスｒｎａワクチン
|
|
JP2023512519A
(ja)
|
2020-01-31 |
2023-03-27 |
ベス イスラエル ディーコネス メディカル センター インコーポレイテッド |
コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
|
|
CN113215178B
(zh)
|
2020-02-03 |
2023-09-08 |
康希诺(上海)生物科技有限公司 |
用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
|
|
KR20220144416A
(ko)
*
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
US11241493B2
(en)
*
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
US12194089B2
(en)
*
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CN111821433B
(zh)
|
2020-02-06 |
2021-06-08 |
深圳市瑞吉生物科技有限公司 |
mRNA疫苗及其合成方法、试剂盒
|
|
BR112022015565A2
(pt)
|
2020-02-07 |
2022-09-27 |
Modernatx Inc |
Vacinas de domínio de mrna para sars-cov-2
|
|
WO2021160036A1
(en)
|
2020-02-10 |
2021-08-19 |
Versitech Limited |
Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof
|
|
WO2021163365A1
(en)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|
|
EP4103722A4
(en)
|
2020-02-11 |
2024-05-22 |
Cytonus Therapeutics, Inc. |
RAPID VACCINE PLATFORM
|
|
EP4103584A4
(en)
|
2020-02-12 |
2024-08-07 |
La Jolla Institute for Immunology |
NOVEL CORONAVIRUS T-CELL EPITOPES AND RELATED USES
|
|
AU2021219847A1
(en)
|
2020-02-12 |
2022-10-13 |
Massachusetts Institute Of Technology |
Field deployable CRISPR-Cas diagnostics and methods of use thereof
|
|
CN113186203B
(zh)
|
2020-02-13 |
2022-12-30 |
斯微(上海)生物科技股份有限公司 |
治疗或者预防冠状病毒病的疫苗试剂
|
|
CA3167611A1
(en)
|
2020-02-13 |
2021-08-19 |
Etienne Simon-Loriere |
Nucleic acid vaccine against the sars-cov-2 coronavirus
|
|
CA3166811A1
(en)
|
2020-02-13 |
2021-08-19 |
Nicolas Robert Xavier Escriou |
Measles-vectored covid-19 immunogenic compositions and vaccines
|
|
EP4103231A4
(en)
|
2020-02-14 |
2024-03-27 |
Geovax, Inc. |
VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
|
|
GB202004007D0
(en)
|
2020-03-19 |
2020-05-06 |
Immodulon Therapeutics Ltd |
Coronavirus
|
|
MX2022009943A
(es)
|
2020-02-14 |
2022-10-18 |
Etherna Immunotherapies Nv |
Vacunas intranasales de arnm.
|
|
IL295548A
(en)
|
2020-02-14 |
2022-10-01 |
Altimmune Inc |
Immunogenic compositions of the corona virus and their uses
|
|
EP4103234A4
(en)
|
2020-02-14 |
2025-03-12 |
Epivax, Inc. |
T-cell epitope clusters and related compounds for the prevention, diagnosis, and treatment of COVID-19
|
|
WO2021163438A1
(en)
|
2020-02-14 |
2021-08-19 |
University Of Washington |
Polypeptides, compositions, and their use to treat or limit development of an infection
|
|
CN111228475A
(zh)
|
2020-02-21 |
2020-06-05 |
赛诺（深圳）生物医药研究有限公司 |
用于预防新型冠状病毒的生物制品
|
|
US20210283244A1
(en)
|
2020-02-23 |
2021-09-16 |
Guangzhou N Biomed Ltd. |
Adenovirus-vectored vaccine for preventing sars-cov-2 infection
|
|
CN111333704B
(zh)
|
2020-02-24 |
2021-01-12 |
军事科学院军事医学研究院微生物流行病研究所 |
新型冠状病毒covid-19疫苗、制备方法及其应用
|
|
CN112300251B
(zh)
|
2020-02-24 |
2022-04-05 |
成都威斯克生物医药有限公司 |
抗SARS-CoV-2感染的蛋白及疫苗
|
|
KR20230104068A
(ko)
|
2020-03-31 |
2023-07-07 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
뉴클레오사이드 변형 mRNA를 사용한 범용 인플루엔자 백신
|
|
CN111647053A
(zh)
|
2020-04-16 |
2020-09-11 |
军事科学院军事医学研究院生命组学研究所 |
多肽及其在新型冠状病毒检测、抗体或疫苗筛选中的应用
|
|
WO2021209970A1
(en)
|
2020-04-16 |
2021-10-21 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
CA3176481A1
(en)
|
2020-04-22 |
2021-10-28 |
Marjoh NAUTA |
Coronavirus vaccine
|
|
IL297419B2
(en)
|
2020-04-22 |
2025-02-01 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
CN111518175B
(zh)
|
2020-05-11 |
2021-02-26 |
广东珩达生物医药科技有限公司 |
Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
|
|
CA3183086A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
KR20230025670A
(ko)
|
2020-05-19 |
2023-02-22 |
그릿스톤 바이오, 인코포레이티드 |
Sars-cov-2 백신
|
|
CN111606980B
(zh)
|
2020-05-27 |
2021-10-26 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s2蛋白多肽及其应用
|
|
CN111606981B
(zh)
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
US11078242B1
(en)
|
2020-05-28 |
2021-08-03 |
Sotira Covid, Llc |
Peptides for Covid-19 prevention and treatment
|
|
WO2021243122A2
(en)
|
2020-05-29 |
2021-12-02 |
Board Of Regents, The University Of Texas System |
Engineered coronavirus spike (s) protein and methods of use thereof
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
CN111732638B
(zh)
|
2020-07-02 |
2022-01-25 |
重庆博唯佰泰生物制药有限公司 |
一种针对SARS-CoV-2的疫苗
|
|
CN111778264B
(zh)
|
2020-07-14 |
2021-06-29 |
广州佰芮慷生物科技有限公司 |
基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗
|
|
CN112390863B
(zh)
|
2020-09-23 |
2022-11-01 |
厚朴生物科技（苏州）有限公司 |
改造的新冠病毒Spike蛋白胞外结构域及其应用
|
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
CN112266411B
(zh)
|
2020-09-25 |
2022-06-24 |
北京诺思兰德生物技术股份有限公司 |
一种新型冠状病毒疫苗及其应用
|
|
CN112226445B
(zh)
|
2020-10-20 |
2021-05-11 |
成都欧林生物科技股份有限公司 |
编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
|
|
WO2022110099A1
(en)
|
2020-11-30 |
2022-06-02 |
Guangzhou Argorna Biopharmaceuticals Co., Ltd. |
Coronavirus vaccines and uses thereof
|
|
JP2024503699A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
バリアント株ベースのコロナウイルスワクチン
|
|
WO2022155524A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
WO2022180219A1
(en)
|
2021-02-25 |
2022-09-01 |
Kosmatopoulos Kostantinos Kostas |
Optimized vaccine to elicit a t cell immunity against sars-cov-2
|
|
WO2023051701A1
(zh)
|
2021-09-29 |
2023-04-06 |
成都威斯津生物医药科技有限公司 |
抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
|
|
WO2023064907A1
(en)
|
2021-10-15 |
2023-04-20 |
Yale University |
Compositions and methods for vaccination against pathogenic coronavirus species and variants
|
|
US20250000968A1
(en)
|
2021-11-12 |
2025-01-02 |
The United States of America, as represented by the Secretary,Department of Health and Human Service |
Sars-cov-2 spike fused to a hepatitis b surface antigen
|